Novartis (NYSE:NVS) Shares Gap Down – What’s Next?

Novartis AG (NYSE:NVS) shares gapped down prior to trading on Tuesday . The stock had previously closed at $159.99, but opened at $139.94. Novartis shares last traded at $139.4910, with a volume of 1,588,628 shares traded.

Key Headlines Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis reaffirmed its sales guidance through 2030 despite the latest clinical setback, providing some reassurance that near-term performance remains supported by its existing portfolio. Novartis announces trial setback on del-desiran drug
• Positive Sentiment: Analysts continue to identify potential upside from remibrutinib, which Bank of America estimates could generate approximately $3 billion in peak annual multiple-sclerosis sales if successfully approved and commercialized. Novartis has a potential $3 billion MS opportunity
• Neutral Sentiment: Broader risk-off trading, including sharply lower U.S. stock futures, contributed to selling across large pharmaceutical and biotechnology stocks, amplifying Novartis-specific weakness. Novartis and other stocks moving lower
• Neutral Sentiment: Industry concerns over potential U.S. tariffs on imported generic medicines could pressure drug manufacturers and prices, although the warning came from Sandoz and is not a direct Novartis announcement. Swiss pharma CEO warns of generic drug tariff threat
• Negative Sentiment: Novartis said its late-stage del-desiran study for myotonic dystrophy failed to meet a key efficacy measure. The therapy was acquired through the company’s roughly $12 billion purchase of Avidity Biosciences, raising questions about the value and execution of that pipeline investment. Novartis del-desiran trial disappointment
• Negative Sentiment: Pelacarsen failed to reduce cardiovascular events in a late-stage study despite lowering Lp(a) cholesterol. The result undermines prospects for a potentially multibillion-dollar cardiovascular treatment and increases pressure on Novartis to deliver successful pipeline launches. Cholesterol drug setback casts doubt over multibillion-dollar race

Analyst Upgrades and Downgrades

NVS has been the topic of a number of recent analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Citigroup reaffirmed a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $141.20.

Novartis Price Performance

The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. The firm has a market capitalization of $264.81 billion, a P/E ratio of 20.95, a PEG ratio of 3.12 and a beta of 0.45. The company’s 50 day moving average price is $155.79 and its 200 day moving average price is $153.67.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The firm had revenue of $14.95 billion during the quarter. As a group, sell-side analysts anticipate that Novartis AG will post 8.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Novartis

Institutional investors and hedge funds have recently made changes to their positions in the company. Morgan Stanley lifted its stake in shares of Novartis by 14.9% during the fourth quarter. Morgan Stanley now owns 8,876,906 shares of the company’s stock valued at $1,223,860,000 after acquiring an additional 1,148,033 shares during the period. Fisher Asset Management LLC increased its position in Novartis by 3.1% in the fourth quarter. Fisher Asset Management LLC now owns 7,465,850 shares of the company’s stock worth $1,029,317,000 after purchasing an additional 226,484 shares during the period. Bank of America Corp DE raised its holdings in Novartis by 9.1% during the 1st quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock worth $758,067,000 after purchasing an additional 413,778 shares during the last quarter. Auto Owners Insurance Co lifted its position in Novartis by 13,687.0% during the 4th quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock valued at $638,103,000 after purchasing an additional 4,594,726 shares during the period. Finally, Franklin Resources Inc. lifted its position in Novartis by 10.3% during the 4th quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company’s stock valued at $617,562,000 after purchasing an additional 419,988 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.